Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                           THE SECURITIES ACT OF 1934

        Date of report (Date of earliest event reported): August 14, 2002

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

           Delaware                    000-14879                  222322400
(State or Other Jurisdiction    (Commission File Number)       (IRS Employer
       of Incorporation)                                     Identification No.)

600 College Road East, CN 5308, Princeton, NJ                           08540
(Address of Principal Executive Offices)                              (Zip Code)

                                 (609) 750-8200
                         (Registrant's telephone number,
                              including area code)

          (Former Name or Former Address, if Changed Since Last Report)

         Item 5.     Other Events.

     On August 14, 2002,  Cytogen  Corporation  (the  "Company")  issued a press
release  reporting  that  it  was  notified  by the  Nasdaq  Stock  Market  Inc.
("Nasdaq")  regarding the Company's  non-compliance with the minimum closing bid
price requirement  relating to Cytogen Common Stock. The Company has 90 calendar
days or until November 12, 2002 to regain  compliance with the minimum bid price
requirement of $1.00 per share.

     There can be no  assurance  that the Company  will be able to maintain  the
listing of its Common Stock on Nasdaq  National  Market.  Such  delisting of its
Common Stock could make it difficult for the Company to obtain future  financing
and materially adversely affect the trading in and price of the Common Stock.

         Item 7.     Financial Statements, Pro Forma Financial Information
and Exhibits.

         (c) Exhibits.

              Exhibit No.    Description
              -----------    -----------
                 99.1        Press release of the Company dated August 14, 2002


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                 Cytogen Corporation

                                                 By: /s/ Lawrence R. Hoffman
                                                      Lawrence R. Hoffman,
                                                       Chief Financial Officer

Date:  August 19, 2002